PRESS RELEASE

from Arix Bioscience PLC (isin : GB00BD045071)

Correction: Result of Annual General Meeting

Arix Bioscience PLC (ARIX)
Correction: Result of Annual General Meeting

24-May-2023 / 07:00 GMT/BST


 

 

The following amendment has been made to the ‘Arix Bioscience plc Result of Annual General Meeting' announcement released on 23/05/2023 at 16:30 under EQS News ID 1639935.

 

Website links to the full details of the Arix investor relations website and National Storage Mechanism have been reinserted, owing to a text conversion error on the EQS platform.

 

All other information remains unchanged. The fully amended text is shown below:

 

Arix Bioscience plc

 

Result of Annual General Meeting

 

LONDON, 24 May 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.

 

Full details of the poll results are set out below and will also be available on the Company's website at: https://arixbioscience.com/investor-relations/document-library?folder=AGM&year=

 

No

RESOLUTION

VOTES FOR

%

VOTES AGAINST

%

TOTAL VOTES

% of ISC VOTED

VOTES WITHHELD

1

To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2022

68,931,411

100.00%

3,441

0.00%

 

68,934,852

 

 

53.28%

 

 

8,440

 

2

To approve the Directors' Remuneration Report

61,073,950

 

89.25%

 

 

7,358,207

 

 

10.75%

 

68,432,157

 

52.89%

 

 

511,135

 

3

To re-elect Peregrine Moncreiffe as a Director

68,099,019

 

98.79%

 

 

834,821

 

 

1.21%

 

68,933,840

 

53.28%

 

 

9,452

 

4

To re-elect Maureen O'Connell as a Director

68,894,053

 

99.94%

 

 

42,077

 

 

0.06%

 

68,936,130

 

53.28%

 

 

7,162

 

5

To re-elect Isaac Kohlberg as a Director

68,900,656

 

99.98%

 

 

17,184

 

 

0.02%

 

68,917,840

 

53.26%

 

 

25,452

 

6

To re-elect Robert Lyne as a Director

 

68,902,689

 

 

99.95%

 

 

31,595

 

 

0.05%

 

68,934,284

 

53.28%

 

 

9,008

 

7

To elect Dr. Debra Barker as a Director

68,907,528

 

99.95%

 

 

32,248

 

 

0.05%

 

68,939,776

 

53.28%

 

 

3,516

 

8

To elect Andrew Smith as a Director

 

68,921,195

 

 

99.98%

 

 

13,089

 

 

0.02%

 

68,934,284

 

53.28%

 

 

9,008

 

9

To appoint BDO LLP as auditors of the Company

68,929,881

 

99.99%

 

 

7,445

 

 

0.01%

 

68,937,326

 

53.28%

 

 

5,966

 

10

To authorise the Audit and Risk Committee of the Company to fix the auditor's remuneration

68,934,245

 

100.00%

 

 

2,013

 

 

0.00%

 

68,936,258

 

53.28%

 

 

7,034

 

11

To authorise the Directors to allot shares

65,989,256

 

95.72%

 

 

2,950,520

 

 

4.28%

 

68,939,776

 

53.28%

 

 

3,516

 

12

Authority to disapply statutory pre‐ emption rights

62,199,252

 

90.23%

 

 

6,734.680

 

 

9.77%

 

68,933,932

 

53.28%

 

 

9,360

 

13

Additional authority to disapply statutory pre‐ emption rights

62,202,105

 

90.23%

 

See all Arix Bioscience PLC news